Mangrove Partners’s bluebird bio BLUE Stock Holding History

Mangrove Partners’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-8,539	Closed	-$1.71M	–	459
2021 Q4	$1.71M	Sell	8,539 -5,016	-37%	-$1.18M	0.1%	380
2021 Q3	$3.35M	Buy	13,555 +1,884	+16%	+$539K	0.3%	98
2021 Q2	$4.83M	Sell	11,671 -1,853	-14%	-$734K	0.5%	49
2021 Q1	$5.28M	Buy	+13,524	New	+$6.66M	0.53%	36
2020 Q4	–	Sell	-21,854	Closed	-$15.3M	–	102
2020 Q3	$15.3M	Buy	21,854 +11,847	+118%	+$9.24M	1.93%	15
2020 Q2	$7.91M	Buy	+10,007	New	+$7.55M	1.93%	19

Other funds holding BLUE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Mangrove Partners's BLUE Position: Q1 2022 in Review

Mangrove Partners sold out of bluebird bio (BLUE) in Q1 2022, closing a stake of 8,539 shares — an estimated $1.71M sold.

Mangrove Partners first reported a position in BLUE in Q2 2020 and held it in 6 quarters. The position peaked at $15.3M in Q3 2020. 174 funds tracked by Wall St. Rank hold BLUE as of Q1 2022.

Mangrove Partners reported no remaining bluebird bio position as of Q1 2022 after selling out during the quarter.
Mangrove Partners sold 8,539 bluebird bio shares in Q1 2022, an estimated $1.71M.
Mangrove Partners first reported a position in bluebird bio in Q2 2020 and held it in 6 quarters.
Mangrove Partners's bluebird bio position peaked at $15.3M in Q3 2020.
174 funds tracked by Wall St. Rank held bluebird bio as of Q1 2022.

Based on Mangrove Partners's 13F filing for Q1 2022, filed 16 May 2022.